Business Context and Reporting Period
Company: Coherus Oncology, Inc. (formerly Coherus BioSciences, Inc.)
Filing Type: Form 10-Q
Period: Quarter ended June 30, 2025
Coherus Oncology is a commercial-stage innovative oncology company focused on its approved PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline of immuno-oncology candidates. In May 2025, the company changed its name to reflect its exclusive focus on oncology following the divestiture of its biosimilar businesses (UDENYCA, YUSIMRY, and CIMERLI). The UDENYCA franchise was sold to Intas Pharmaceuticals in April 2025 for $483.4 million, qualifying as discontinued operations.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Revenue (Continuing Ops) | $10.3 million | $10.3 million | $17.9 million | $12.6 million |
| Net Income (Loss) | $297.8 million | $(12.9) million | $241.2 million | $90.0 million |
| Net Loss from Continuing Ops | $(44.9) million | $(54.9) million | $(92.3) million | $(122.9) million |
| Net Income from Discontinued Ops | $342.6 million | $41.9 million | $333.5 million | $212.8 million |
| Cash and Cash Equivalents | $216.9 million | $126.0 million (Dec 31, 2024) | As of June 30, 2025 | |
| Total Debt (Non-Current) | $36.9 million | $264.9 million (Dec 31, 2024) | As of June 30, 2025 |
Note: Net Income for Q2 2025 is driven primarily by a $339.1 million gain on the sale of the UDENYCA business, classified as discontinued operations. Continuing operations remain loss-making.
Material Changes vs. Prior Period
- Revenue Growth: LOQTORZI revenue increased 163% year-over-year for the six months ended June 30, 2025 ($17.3 million vs. $5.8 million), driven by volume growth since its December 2023 launch. Total net revenue from continuing operations increased 42% YTD.
- Discontinued Operations: The company recognized a net gain of $339.1 million from the UDENYCA sale in Q2 2025. This contrasts with Q2 2024, which included a $24.1 million gain from the YUSIMRY sale.
- Debt Reduction: The company repurchased substantially all of its 2026 Convertible Notes ($230 million principal) in April and May 2025 using proceeds from the UDENYCA sale. Remaining debt consists primarily of a $38.7 million 2029 Term Loan.
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased 23% YTD ($52.1 million vs. $67.7 million) due to lower headcount and the absence of a $6.8 million impairment charge recorded in Q1 2024.
Guidance, Outlook, and Risks
Outlook: Management expects net revenue from continuing operations in 2025 to be higher than 2024 due to LOQTORZI growth. R&D expenses are expected to increase in 2025 due to investments in the immuno-oncology pipeline (casdozokitug and CHS-114).
Key Risks and Contingencies:
- Nasdaq Compliance: The company received notice that its stock bid price closed below $1.00 for 30 consecutive days. It has until December 29, 2025, to regain compliance or risk delisting.
- Internal Controls: A material weakness in internal control over financial reporting regarding inventory account reconciliations was identified in 2024. While remediation steps are underway, the specific control was decommissioned with the UDENYCA sale, preventing formal retesting in the current period.
- Earnout Payments: The company is eligible for two potential earnout payments of $37.5 million each from Intas based on future UDENYCA net sales thresholds, but receipt is not guaranteed.
- Liquidity: The company believes its cash, marketable securities, and ATM offering capacity ($64.9 million remaining) are sufficient to fund operations for at least 12 months.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the sustainability of earnings by excluding the one-time $339.1 million gain from the UDENYCA sale; continuing operations generated a net loss of $44.9 million in Q2 2025.
- LOQTORZI Trajectory: Confirm the rate of LOQTORZI adoption and gross margin trends (67% in Q2 2025 vs. 82% in Q2 2024) as the sole revenue driver for continuing operations.
- Debt Obligations: Review the terms of the remaining 2029 Term Loan ($38.7 million) and the Revenue Purchase and Sale Agreement liability ($13.1 million) to assess future cash flow requirements.
- Stock Listing Status: Monitor the company's stock price to ensure it meets the $1.00 minimum bid price requirement for Nasdaq listing by the December 2025 deadline.
- Internal Control Remediation: Assess the progress of remediation for the material weakness in inventory controls and the potential for future restatements or reporting delays.